Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

Novo Nordisk A/S said it has implemented a global hiring freeze as the Danish maker of weight-loss drugs seeks to cut costs ...

It faces more than 1,800 lawsuits consolidated in federal court in Pennsylvania and new claims emerging weekly, according to ...

The side effect is rare, according to a new study, but is also the subject of multiple lawsuits, including two filed by Long ...

Negative Streak Finally Ended Novo Nordisk: Market Still Pricing It At Crisis Valuations From Doubt To Action: Why I Bought ...

The drug is available as a weight-loss medication under the brand name Wegovy and will now also be sold directly to diabetes ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

VK2735 met its primary endpoint but failed to outdo competitors Novo Nordisk and Eli Lilly in terms of body weight loss.

The move is likely part of the company’s goal to reduce costs as it faces increased competition in the GLP-1 space.

Denmark’s economy rebounded in the second quarter, as the strength of the broader pharmaceuticals industry helped to outweigh ...

Viking Therapeutics' stock crashed 40% in early trading on Tuesday after a phase 2 trial of its weight-loss pill showed a ...

A host of women have complained that they are experiencing 'Ozempic vulva' after taking weight loss drugs to shed the pounds.